These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 32927129)
1. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. Tan Q; Duan L; Ma Y; Wu F; Huang Q; Mao K; Xiao W; Xia H; Zhang S; Zhou E; Ma P; Song S; Li Y; Zhao Z; Sun Y; Li Z; Geng W; Yin Z; Jin Y Bioorg Chem; 2020 Nov; 104():104257. PubMed ID: 32927129 [TBL] [Abstract][Full Text] [Related]
2. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539 [TBL] [Abstract][Full Text] [Related]
3. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV. Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605 [TBL] [Abstract][Full Text] [Related]
4. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease. Hajbabaie R; Harper MT; Rahman T Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721 [TBL] [Abstract][Full Text] [Related]
5. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study. Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595 [TBL] [Abstract][Full Text] [Related]
6. Carbon fullerene and nanotube are probable binders to multiple targets of SARS-CoV-2: Insights from computational modeling and molecular dynamic simulation studies. Skariyachan S; Gopal D; Deshpande D; Joshi A; Uttarkar A; Niranjan V Infect Genet Evol; 2021 Dec; 96():105155. PubMed ID: 34823028 [TBL] [Abstract][Full Text] [Related]
7. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases. Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022 [TBL] [Abstract][Full Text] [Related]
8. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. Hoffman RL; Kania RS; Brothers MA; Davies JF; Ferre RA; Gajiwala KS; He M; Hogan RJ; Kozminski K; Li LY; Lockner JW; Lou J; Marra MT; Mitchell LJ; Murray BW; Nieman JA; Noell S; Planken SP; Rowe T; Ryan K; Smith GJ; Solowiej JE; Steppan CM; Taggart B J Med Chem; 2020 Nov; 63(21):12725-12747. PubMed ID: 33054210 [TBL] [Abstract][Full Text] [Related]
10. Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors. Ghosh AK; Shahabi D; Yadav M; Kovela S; Anson BJ; Lendy EK; Bonham C; Sirohi D; Brito-Sierra CA; Hattori SI; Kuhn R; Mitsuya H; Mesecar AD Molecules; 2021 Sep; 26(19):. PubMed ID: 34641337 [TBL] [Abstract][Full Text] [Related]
11. An Updated Review on SARS-CoV-2 Main Proteinase (M Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134 [TBL] [Abstract][Full Text] [Related]
12. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro. Zhang L; Liu J; Cao R; Xu M; Wu Y; Shang W; Wang X; Zhang H; Jiang X; Sun Y; Hu H; Li Y; Zou G; Zhang M; Zhao L; Li W; Guo X; Zhuang X; Yang XL; Shi ZL; Deng F; Hu Z; Xiao G; Wang M; Zhong W Virol Sin; 2020 Dec; 35(6):776-784. PubMed ID: 32910347 [TBL] [Abstract][Full Text] [Related]
13. Virtual screening of phytoconstituents from miracle herb Siddiqui S; Upadhyay S; Ahmad R; Gupta A; Srivastava A; Trivedi A; Husain I; Ahmad B; Ahamed M; Khan MA J Biomol Struct Dyn; 2022 Jun; 40(9):3928-3948. PubMed ID: 33289456 [TBL] [Abstract][Full Text] [Related]
14. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083 [TBL] [Abstract][Full Text] [Related]
16. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors? Amin SA; Banerjee S; Gayen S; Jha T Eur J Med Chem; 2021 Apr; 215():113294. PubMed ID: 33618158 [TBL] [Abstract][Full Text] [Related]
17. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL Du R; Cooper L; Chen Z; Lee H; Rong L; Cui Q Antiviral Res; 2021 Jun; 190():105075. PubMed ID: 33872675 [TBL] [Abstract][Full Text] [Related]
18. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862 [TBL] [Abstract][Full Text] [Related]
19. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*. Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984 [TBL] [Abstract][Full Text] [Related]
20. Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro. Kiba Y; Tanikawa T; Kitamura M Biol Pharm Bull; 2024; 47(5):965-966. PubMed ID: 38763750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]